Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | Q9HBH1 | 2/20 | 0.44 | |
| ▸ | MMP2 | P08253 | 3/20 | 0.44 |
| ▸ | MMP3 | P08254 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324830 | 0.87 | KMT2A (0.52) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL3324827 | 0.87 | KMT2A (0.52) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL6135582 | 0.86 | MMP2 (0.46) | KMT2AMEN1PDFMMP2MMP3 | |
| SCHEMBL13333273 | 0.84 | CCR1 (0.50) | PDFMMP2MMP3BMP1 | |
| SCHEMBL5497357 | 0.84 | MMP2 (0.44) | PDFMMP2MMP3BMP1 | |
| SCHEMBL5497359 | 0.84 | MMP2 (0.44) | PDFMMP2MMP3BMP1 | |
| SCHEMBL14282177 | 0.83 | MEN1 (0.46) | KMT2AMEN1PDFMMP2MMP3 | |
| SCHEMBL7529199 | 0.83 | MMP2 (0.49) | MMP2MMP3BMP1 | |
| SCHEMBL14282181 | 0.83 | PDF (0.52) | PDFMMP2MMP3 | |
| SCHEMBL14282179 | 0.83 | PDF (0.54) | PDFMMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | KMT2A 3725/4885MEN1 2736/4885CNR1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.